Improving Access to Medicines – Pharmaceutical Benefits Scheme – new and amended listings

This measure makes new and amended medicines available on the Pharmaceutical Benefits Scheme (PBS). Since the Mid-Year Economic and Fiscal Outlook in December 2016, the Government has approved 25 new and amended listings that have a fiscal impact (including price changes) on the PBS.

Page last updated: 09 May 2017

PDF version: Improving Access to Medicines – Pharmaceutical Benefits Scheme – new and amended listings (PDF 115 KB)

High cost drug sacubitril with valsartan (Entresto®) will also be listed on the PBS from 1 June 2017, for the treatment of patients with chronic heart failure. This will benefit around 60,340 patients per year. Without subsidy, these patients would pay more than $1,970 per year for treatment with this drug.

Why is this important?

Australian patients are continuing to access life-changing and life-saving medicines under the PBS.

The Government has maintained its commitment to list all medicines on the PBS that have received a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC).

Who will benefit?

New and amended listings on the PBS benefit patients by subsidising new medicines or extending listings to cover new conditions or patient groups.

The approval of ivacaftor (Kalydeco®) on the PBS will benefit children aged two to five with cystic fibrosis who previously did not have access to this treatment.

For the first time, patients suffering from idiopathic pulmonary fibrosis (a debilitating lung disease) will have PBS subsidised access to the medicine nintedanib (Ofev®).

Stakeholders, including patients and pharmaceutical companies, welcome the listings.

The PBAC has recognised that there is a clinical need for new therapies for the treatment of chronic heart failure. Listing sacubitril with valsartan (Entresto®) will provide patients with a new treatment option.

How much will this cost?

The Government will provide $1.2 billion for these new and amended listings from 2016–17 to 2020–21. The costs for some of these medicines are reduced by revenue paid by companies as negotiated. Revenue is not for publication as it is commercial-in-confidence.

In this section